This is a preview of subscription content, log in via an institution to check access.
Reference
Decision Resources. According to Surveyed Oncologists in the EU5, Zytiga Has Heavily Penetrated Second-Line Treatment of Metastatic Castrate-Resistant Prostate Cancer (mCRPC) and is Displacing Jevtana to Later-Line mCRPC. Media Release : 18 Mar 2013. Available from: URL: http://www.decisionresources.com
Rights and permissions
About this article
Cite this article
Abiraterone acetate displacing cabazitaxel to later-line therapy. PharmacoEcon Outcomes News 675, 10 (2013). https://doi.org/10.1007/s40274-013-0293-x
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-013-0293-x